TPST — Tempest Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1544227 ·
Last close
$0.33
Market Cap
$6.54M
52W High
$9.39
52W Low
$0.30
ADV30
203,896
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,823,000 | -3,629,000 | 8,761,000 | 897,000 | 10,591,000 |
| Jun 2026 | 0 | — | -5,250,000 | -5,244,000 | 9,633,000 | 779,000 | 10,723,000 |
| Mar 2026 | 0 | — | -5,539,000 | -27,696,000 | 10,748,000 | 1,805,000 | 9,926,000 |
| Dec 2025 | 0 | — | -4,077,000 | -4,021,000 | 16,931,000 | 7,707,000 | 10,263,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,730,000
Investing CF
$0
Financing CF
$7,229,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.73
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-275,316,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-40,472,000
Pretax Income TTM
$-40,472,000
Interest Exp TTM
$0
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,575,000 | -26,262,000 | 16,931,000 | 10,263,000 | 6,668,000 | -26,820,000 |
| Dec 2024 | 0 | -42,026,000 | -41,843,000 | 41,488,000 | 22,362,000 | 19,126,000 | -33,027,000 |
| Dec 2023 | 0 | -29,157,000 | -29,491,000 | 51,603,000 | 24,835,000 | 26,768,000 | -27,357,000 |
| Dec 2022 | 0 | -34,640,000 | -35,709,000 | 46,089,000 | 27,978,000 | 18,111,000 | -31,072,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-21,184,000
NetIncome TTM
$-40,472,000
OpCashFlow TTM
—
Assets (Latest)
$9,633,000
Forward EPS
$-1.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | $6.43M | $0.45 | — |
| TOVX | Theriva Biologics, Inc. | $6.42M | $0.14 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.71M | $1.88 | — |
| ENVB | Enveric Biosciences, Inc. | $6.31M | $1.41 | — |
| LGVN | Longeveron Inc. | $6.83M | $2.11 | — |
News headlines (Yahoo Finance, 1h cache)
Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-13 21:47 · Yahoo
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
2026-11-11 13:53 · Yahoo
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
2026-10-14 12:00 · Yahoo
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
2026-09-23 12:00 · Yahoo
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
2026-09-15 20:05 · Yahoo
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
2026-09-11 12:00 · Yahoo
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:30 · Yahoo
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:25 · Yahoo
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
2026-07-21 11:00 · Yahoo
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
2026-07-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.